BAM
ICPT

Belpointe Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Belpointe Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50
Closed -$619 – 3884
2022
Q4 		$619 Buy
+50
New +$708 ﹤0.01% 3518
2020
Q3 		– Sell
-2,297
Closed -$110K – 830
2020
Q2 		$110K Sell
2,297
-184
-7% -$14.2K 0.01% 696
2020
Q1 		$156K Buy
+2,481
New +$223K 0.03% 486

Other funds holding ICPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Belpointe Asset Management's ICPT Position: Q1 2023 in Review

Belpointe Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2023, closing a stake of 50 shares — an estimated $619 sold.

Belpointe Asset Management first reported a position in ICPT in Q1 2020 and held it in 3 quarters. The position peaked at $156K in Q1 2020. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

  • Belpointe Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 50 Intercept Pharmaceuticals, Inc. shares in Q1 2023, an estimated $619.
  • Belpointe Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2020 and held it in 3 quarters.
  • Belpointe Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $156K in Q1 2020.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Belpointe Asset Management's 13F filing for Q1 2023, filed 15 May 2023.